Correlation Between Iovance Biotherapeutics and Lexicon Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Iovance Biotherapeutics and Lexicon Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Iovance Biotherapeutics and Lexicon Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Iovance Biotherapeutics and Lexicon Pharmaceuticals, you can compare the effects of market volatilities on Iovance Biotherapeutics and Lexicon Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Iovance Biotherapeutics with a short position of Lexicon Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Iovance Biotherapeutics and Lexicon Pharmaceuticals.

Diversification Opportunities for Iovance Biotherapeutics and Lexicon Pharmaceuticals

0.41
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Iovance and Lexicon is 0.41. Overlapping area represents the amount of risk that can be diversified away by holding Iovance Biotherapeutics and Lexicon Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lexicon Pharmaceuticals and Iovance Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Iovance Biotherapeutics are associated (or correlated) with Lexicon Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lexicon Pharmaceuticals has no effect on the direction of Iovance Biotherapeutics i.e., Iovance Biotherapeutics and Lexicon Pharmaceuticals go up and down completely randomly.

Pair Corralation between Iovance Biotherapeutics and Lexicon Pharmaceuticals

Given the investment horizon of 90 days Iovance Biotherapeutics is expected to generate 0.71 times more return on investment than Lexicon Pharmaceuticals. However, Iovance Biotherapeutics is 1.42 times less risky than Lexicon Pharmaceuticals. It trades about -0.03 of its potential returns per unit of risk. Lexicon Pharmaceuticals is currently generating about -0.14 per unit of risk. If you would invest  1,085  in Iovance Biotherapeutics on August 31, 2024 and sell it today you would lose (153.00) from holding Iovance Biotherapeutics or give up 14.1% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Iovance Biotherapeutics  vs.  Lexicon Pharmaceuticals

 Performance 
       Timeline  
Iovance Biotherapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Iovance Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest uncertain performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.
Lexicon Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Lexicon Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Iovance Biotherapeutics and Lexicon Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Iovance Biotherapeutics and Lexicon Pharmaceuticals

The main advantage of trading using opposite Iovance Biotherapeutics and Lexicon Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Iovance Biotherapeutics position performs unexpectedly, Lexicon Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lexicon Pharmaceuticals will offset losses from the drop in Lexicon Pharmaceuticals' long position.
The idea behind Iovance Biotherapeutics and Lexicon Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Other Complementary Tools

Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets